Tuesday, July 8, 2025
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home National

Bharat Biotech seeks DCGI’s permission to conduct Covaxin booster trials in 2-18 age group

by
3 years ago
in National
A A
Bharat Biotech seeks DCGI’s permission to conduct Covaxin booster trials in 2-18 age group
Share on FacebookShare on Twitter

By Shalini Bhardwaj

New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.

The company has applied for permission a week ago. It has already conducted trials in the age group of 2-18 for two doses of Covaxin.

Recently, Bharat Biotech has also received an Emergency Use Authorisation (EUA) approval for 6-12 years old children for two doses.

Bharat Biotech has also applied for the EUA for the 2-5 years old but Subject Expert Committee (SEC) has asked for more data.

Bharat Biotech is the first company in India who had applied for permission from DCGI to conduct trials of a booster dose in the 2-18 age group.

Currently, the Covaxin is under the national COVID vaccination programme for the above 15-18 age group for two doses and above 18 years old for a precaution dose.

The trials for Bharat Biotech’s intranasal booster on a heterologous group are under trial, according to the sources data collection process is over for the age group above 18 years. (ANI)

ShareTweetSendShareSend

Latest News

Wimbledon: Djokovic resists De Minaur challenge to storm into quarter-finals

BRICS seeking to undermine US interests, will ensure America fairly treated on world stage: White House

PM Modi departs for Brasilia after attending BRICS Summit in Rio de Janeiro

Sean ‘Diddy’ Combs gets standing ovation from fellow inmates after court verdict

A look at ‘Pehla Tu Duja Tu’ song from Ajay Devgn, Mrunal Thakur-starrer ‘Son of Sardaar 2’

Last-minute goals: When seconds shape emotions and rewrite fates

“We were overjoyed when he took 10 wickets..did not remember my problem”: Akash Deep’s sister, who is battling cancer

Andhra: YS Sharmila slams Jagan, Avinash Reddy over COA row; demands urgent action for Kadapa architecture students

Delhi: Interstate gang of bag lifters active on trains, railway premises busted; 4 held

Gujarat tops nation with notable increase of more than 241 sq kms in tree cover outside notified forest areas: FSI report

By Shalini Bhardwaj

New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.

The company has applied for permission a week ago. It has already conducted trials in the age group of 2-18 for two doses of Covaxin.

Recently, Bharat Biotech has also received an Emergency Use Authorisation (EUA) approval for 6-12 years old children for two doses.

Bharat Biotech has also applied for the EUA for the 2-5 years old but Subject Expert Committee (SEC) has asked for more data.

Bharat Biotech is the first company in India who had applied for permission from DCGI to conduct trials of a booster dose in the 2-18 age group.

Currently, the Covaxin is under the national COVID vaccination programme for the above 15-18 age group for two doses and above 18 years old for a precaution dose.

The trials for Bharat Biotech's intranasal booster on a heterologous group are under trial, according to the sources data collection process is over for the age group above 18 years. (ANI)

No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science